Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

robot
Abstract generation in progress

Agenus Inc. has partnered exclusively with BAP Pharma to manage global access programs for its botensilimab (BOT) plus balstilimab (BAL) therapies. This collaboration aims to provide compliant, patient-focused access to BOT+BAL through authorized pathways, including France’s AAC program and named-patient programs in other countries. The partnership will streamline operations and logistics for patients with serious cancers, addressing a growing global demand for these therapies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin